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Human lysozyme (LZ; EC 3.2.1.17), 1 is a 15-kDa single chain protein of 123 amino acids (1) . LZ is present in many human cells and tissues, as well as in soluble form in various body fluids, such as serum, umbilical cord serum, urine, cerebrospinal and amniotic fluid, and most secretion fluids, including gastric juice, bile, saliva, tears, seminal fluid, and milk (2, 3) . LZ is found in human milk at a concentration higher than in milk from other animal species (4). However, LZ is a minor whey component of human milk compared with secretory IgA, lactoferrin, and ␣-lactalbumin (5). LZ is a glycosyl hydrolase, cleaving the ␤-1,4 bonds between N-acetylglucosamine and Nacetylmuramic acid (6) . By hydrolyzing the peptidoglycans of procaryote cell walls, human milk LZ has a bacteriolytic function and plays a role, together with secretory IgA and lactoferrin, in the passive protection of breast-fed newborns (7, 8) . Human milk LZ and ␣-lactalbumin are also evolutionarily related, with conservation of the position of four disulfide bonds and of 40% of amino acid residues (9) . Immunoassays of milk LZ should use antibodies that do not cross-react with ␣-lactalbumin.
Several methods of quantitation of LZ in milk have been reported, such as fast protein liquid chromatography (10), polyacrylamide gel electrophoresis (11), enzyme activity assessment (12, 13) , and immunoassays (14 -16) . Enzyme activity, inducing the lysis of Micrococcus lysodeikticus, is commonly measured in human body fluids by turbidimetric (17) , nephelometric (18) , and lysoplate (19) techniques. Immunochemical quantitation of LZ uses immunoelectrophoresis (20) , radioimmunoassay (21), enzyme-linked immunosorbent assay (22) , and classical immunonephelometry (23, 24) . As previously pointed out (14, 17, 18, (22) (23) (24) , most of these methods are lacking in sensitivity and require pretreatment of the samples and, sometimes, a long incubation period.
Microparticle-enhanced nephelometric immunoassays have been previously described as sensitive and accurate techniques for the determination of various human serum proteins (25) and of the main components of bovine milk (26) . Such immunoassays are based on the nephelometric quantification of the inhibition of microparticle-antigen conjugate immunoagglutination by the antigen to be assayed (27) . Microparticle-enhanced nephelometric immunoassays have been applied more recently to the measurement of ␣-lactalbumin (28) , lactoferrin (29) , and ␤-casein (30) in human milk. In such applications, they present the advantages of requiring no pretreatment other than high dilution and of using a single technique for assaying the main proteins of the complex medium that is human milk.
Here, we report the development of a microparticleenhanced nephelometric immunoassay of LZ in human milk and its application to the investigation of the quantitative changes in milk LZ during the first 12 weeks of lactation. The method assessed in milk was then applied to the determination of LZ in other human body fluids (serum, saliva, and urine). Finally, the analytical performances of the microparticle-enhanced nephelometric immunoassay and of the most frequently used other LZ assays were compared.
Materials and Methods reagents
Human milk LZ (280 000 units/mg protein) and human milk ␣-lactalbumin were obtained from Sigma Chemical Co. The purified immunoglobulin fraction of rabbit anti-LZ antiserum (anti-LZ As) was provided by Dako. All traces of non-anti-LZ contaminating antibodies had been removed by the manufacturer of this As, using solidphase adsorption with human plasma and urine proteins. The specific reaction against human LZ was ascertained using crossed immunoelectrophoresis, which revealed that the LZ precipitation arc appears only against concentrated urine from patients with monocytic leukemia and that no precipitation is observed against nondiseased human plasma or concentrated nondiseased human urine.
Polyfunctional hydrophilic microspheres (MSs) of 300 Ϯ 12 nm diameter, synthesized as previously reported (31) , were supplied by Sanofi-Diagnostics-Pasteur. They were covalently coated with human LZ through the formation of imine bonds (27) between the ⑀ amino groups of LZ (0.3 g/L) and the aldehyde groups on MSs (10 g/L). After unreacted aldehyde groups were blocked, the MS-LZ conjugate was recovered by centrifugation and stored at Ϫ20°C, at 3.3 g/L, in a sucrose solution (50 g/L) supplemented with polyethylene glycol 6000 (50 g/L) and NaN 3 (2 g/L).
Human milk samples used for evaluation of immunoassay development and for investigation of the changes in milk LZ concentration during lactation were collected from 74 mothers, who had volunteered, at the maternity hospital of Nancy (France) or at home. The 636 samples were colostrum from days 1-5 postpartum (168 samples), transitional milk obtained days 6 -14 (182 samples), and 286 mature milk samples obtained days 15-28 (167 samples), days 29 -42 (63 samples), days 43-56 (28 samples), and days 57-84 postpartum (28 samples). All milk samples were frozen immediately after collection and stored at Ϫ20°C until use. They were thawed at 40°C in a water bath and vigorously homogenized immediately before analysis. Total protein concentration in these human milk samples was determined by the Bradford method (32) .
Serum, saliva, and urine samples were obtained from healthy subjects (18 -60 years old) and stored at Ϫ20°C until assay. Blood (n ϭ 30), randomly chosen from samples assayed for other purposes, was allowed to coagulate. Whole unstimulated saliva (n ϭ 30) was collected by the draining method (33), then centrifuged for 3 min at 1000g. Urine samples (n ϭ 50) were prepared by centrifugation for 15 min at 3000g.
assay of milk lz
Microparticle-enhanced nephelometric immunoassay of milk LZ was performed as follows: 30 L of unknown or control milk (600-fold dilution) or five serial dilutions (from 1:400 to 1:6400) of the solution of human LZ used as calibrator (1.0 g/L in 0.1 mol/L phosphate buffer, pH 7.2, containing 0.1 mol/L NaCl) and 30 L of anti-LZ As (90-fold dilution) were mixed with 90 L of a nephelometry buffer (0.05 mol/L borate buffer, pH 8, containing 0.1 mol/L NaCl, 1.5 mmol/L Na 2 -EDTA, 30 mmol/L NaN 3 , 2 g/L Triton X-100, and 30 g/L polyethylene glycol 6000) in a reaction microcuvette (Nephelia ® microcuvette, Sanofi-Diagnostics-Pasteur). After an incubation period of 30 min at room temperature, MS-LZ conjugate (25 L, 3.3 g/L) and nephelometry buffer (125 L) were added. All predilutions were performed in the nephelometry buffer with an automated dilutor (Hamilton). The scattered light was measured with the Sanofi-Diagnostics-Pasteur nephelometer Nephelia N600 (34) after incubation for 1 h at room temperature.
Reproducibility of the calibration curves was estimated by measuring light scattering for each dilution of the LZ calibrator in 10 successive assays. The precision of the immunoassay was assessed by measuring LZ in human milk samples with low, intermediate, and high concentrations 30 times during the same assay (within-run precision) and in 10 successive assays (between-run precision).
Analytical recovery was tested in a dilution-overloading experiment: the dilution assay was performed on two serial dilutions (1:150 -1:1200 and 1:200 -1:1600) of one milk sample containing 0.26 g/L of LZ; the overloading assay was performed in one milk sample (0.25 g/L) overloaded by eight increasing amounts of purified LZ (from 0.03 to 0.60 g/L). The slopes calculated by linear regression analysis for the dilution and the overloading assays were compared using Student's t-test. For the total recovery, including dilution and overloading assays, the null hypothesis H 0 (intercept ϭ 0 and slope ϭ 1) vs the alternative hypothesis H 1 (intercept 0 and slope 1) were tested by F (Fisher) and t-tests, respectively, for intercept and slope.
Possible interference of ␣-lactalbumin in LZ determination in human milk was assayed by overloading aliquots of one milk sample (0.33 g/L of LZ, 2.2 g/L of Clinical Chemistry 44, No. 8, 1998 ␣-lactalbumin) with four increasing amounts of purified ␣-lactalbumin (from 1.1 to 4.9 g/L). Linear regression parameters of LZ recovery in these loaded samples were analyzed as above.
application in other body fluids
Microparticle-enhanced nephelometric immunoassays of LZ in serum, saliva, and urine followed the same procedure that used in human milk. However, six serial dilutions (from 1:400 to 1:12 800) of the solution of human LZ used as calibrator were used to obtain larger calibration curves. Serum and saliva samples were 10-fold prediluted, and urine samples were assayed pure (30 L, for a final reaction mixture of 300 L).
Results

ms-lz conjugate
Preliminary studies, performed in various conditions of MS coating, showed that the most immunoreactive MS-LZ conjugate was obtained with the conditions given in Materials and Methods. The MS-LZ conjugate remained immunoreactive for at least 6 months when stored at Ϫ20°C. It was agglutinated by serial dilutions of anti-LZ As, and the light scattered by conjugate clusters formed during this immunoagglutination could be quantified by nephelometry.
Agglutination of MS-LZ conjugate (275 mg/L) with anti-LZ As (900-fold diluted) was progressively inhibited by graded concentrations of free LZ (8 -500 g/L in the reaction mixture). Fifty percent inhibition was observed with 67 g/L LZ, and a minimal concentration of 8 g/L was detectable in the reaction mixture as yielding an intensity of light scattered 3 SD lower than the mean value obtained in the absence of LZ (0% inhibition).
milk lz assay
The inhibition of MS-LZ conjugate immunoagglutination by five serial concentrations of free LZ, from 16 to 250 g/L, in the reaction mixture was used to establish the calibration curve of LZ assay. A calibration range from 0.09 to 1.5 g/L of LZ in whole human milk (Fig. 1) was thus obtained when the assay was performed, as indicated in Materials and Methods, with milk samples diluted 6000-fold in the reaction mixture. Reproducibility CVs (n ϭ 10) of the light scattering measured for each concentration of the LZ calibrator used for calibration were Ͻ4%.
The precision of the milk LZ immunoassay was assessed by the CVs obtained in within-and between-run studies (from 1% to 5%) as shown in Table 1 . Analytical recovery (Fig. 2) was linear (n ϭ 16, r ϭ 0.994, P Ͻ0.001) for the range of LZ concentrations in human milk tested in dilution-overloading assays (0.1-1.0 g/L). A mean percentage of recovery of 101% (SD, 10%) was obtained. The slopes of the dilution (0.932) and overloading (1.051) curves were not significantly different (P Ͼ0.05). The slope (0.960) and the intercept (0.013 g/L) of the total recovery curve, including dilution and overloading assays, were not significantly different (P Ͼ0.05) from 1 and 0, respectively. Increasing amounts of ␣-lactalbumin added in milk samples did not interfere with LZ assay (Fig. 2) : a mean percentage of recovery of 103.3% (SD, 3.3%) was obtained for LZ measurement, and the slope (0.004) of the ␣-lactalbumin overloading assay was not significantly different from 0 (P Ͼ0.05).
application to human milk samples
Application of the microparticle-enhanced nephelometric immunoassay of LZ to 636 human milk samples allowed us to obtain the following global results: minimum, 0.09 g/L; maximum, 1.83 g/L; mean, 0.32 g/L. Changes in milk LZ concentration and in the proportion of LZ in milk total proteins were observed according to the stage of lactation (Fig. 3) . The global concentration per liter was significantly higher (P Ͻ0.05) in colostrum from days 1-5 (n ϭ 168; mean, 0.36 g/L; SD, 0.27 g/L) than in transitional milk from days 6 -14 (n ϭ 182; mean, 0.30 g/L; SD, 0.19 g/L) and remained stable in the mature milk from 
Discussion
Nephelometric measurement of the inhibition of MS-LZ conjugate immunoagglutination by free LZ allowed the development of a microparticle-enhanced nephelometric immunoassay for human LZ. As mentioned by its manufacturer, the specificity of the anti-LZ As used in this immunoassay was ascertained using crossed immunoelectrophoresis against concentrated urine from patients with monocytic leukemia, concentrated nondiseased urine, and nondiseased human plasma. In spite of the conservation of 40% of amino acid residues between human ␣-lactalbumin and LZ (9) , no interference was observed in a experiment in which human milk was overloaded with high amounts of human ␣-lactalbumin. The microparticle-enhanced nephelometric immunoassay of LZ thus developed in human milk is easy to perform, without washing or phase separation, and rapid (90 min, 240 results/h), allowing LZ measurement in large series of milk samples. The concentration of LZ in milk can be measured over a large calibration range (from 0.09 to 1.50 g/L) with high reproducibility (CVs Ͻ5% within and between runs) and accuracy (linear recovery in dilution-overloading assay). The inhibition mode chosen protects against the risk of underestimation by antigen excess. The lower detection limit (8 g/L) allows to use high dilutions of milk samples, cancelling sample blank measurement and such clarifying pretreatment as skimming or casein precipitation.
In comparison, the mostly used methods for LZ deter- [17] [18] [19] , and conventional immunonephelometry, 1 mg/L (23, 24) ); the need to pretreat samples (17, 19, 23, 24) ; the possible action of factors in biological fluids that alter the enzymatic activity of LZ (35); a long incubation period (18 h were necessary to obtain reliable results by the lysoplate technique (19) ); the constraints because of washing and phase separation (21) or the use of radioisotopes (22) ; and the risk of underestimation by antigen excess, which may be encountered in immunoassays based on a noncompetitive antigen-antibody reaction (21, 23, 24) . The concentrations of LZ measured by this microparticle-enhanced nephelometric immunoassay in 636 human milk samples, collected from 74 mothers and including colostrum and transitional and mature milks, were individually distributed over a large range (0.09 -1.83 g/L) with mean concentrations ranging from 0.30 to 0.83 g/L in relation with the lactation stage. The comparison of these mean concentrations of LZ in human milk with those (0.02-1.5 g/L) previously reported (10 -16) was difficult because of the lack of standard material. These last results were, incidentally, highly debated according to the methods used to obtain them, whether they were enzymatic or immunochemical determinations, and in terms of LZ standards and sample pretreatment (14, 22, 24) .
The large distribution of milk LZ concentrations reflected both great individual variability and the influence of the stage of lactation. Variations in LZ concentrations of human milk, in relation with age, parity, maturity of pregnancy, and the mother's diet, have already been reported (12) (13) (14) (15) (16) . Important changes in the absolute LZ concentrations in human milk during lactation were also observed previously (10 -15) . Our results, showing a nadir of LZ concentration (0.30 g/L) from 2 to 6 weeks of lactation and a progressive increase (0.83 g/L during the third month) are similar to these reported in other studies. The constant increase of the relative concentration of LZ among milk total proteins from colostrum (1.7%) to mature milk from days 43-56 (3.8%) can be identified as being principally the consequence of the decrease (from 22 to 10 g/L) of the total protein content of human milk during the same period. Such decreases occur earlier for secretory IgA (14) and lactoferrin (29) , and are more staggered for ␣-lactalbumin (28) and ␤-casein (30) . The strong increase of the relative milk LZ concentration after the second month of lactation (7.3% in mature milk from days 57-84), at a time when the total protein content of human milk slightly increases again (11 g/L), suggests that LZ, as well as lactoferrin (29) , could play a major part as antiinfectious agents in the passive protection of breastfed infants during mature lactation. They could also be involved in the local protection of the mammary gland itself.
A microparticle-enhanced nephelometric immunoassay of LZ was applied here in a large series of human milk samples to study quantitative changes during lactation. Because of its ease and rapidity, such an immunoassay could also be an appropriate method for allowing an exhaustive investigation of LZ milk changes in relation to the mother's status. The applicability of microparticleenhanced nephelometric immunoassays in various body fluids has been reported previously (25, 26, 34, 36) . The present application to the determination of LZ in serum and saliva, the results of which were close to those previously reported (3, 19, 20, 23, 24) , suggests that microparticle-enhanced nephelometric immunoassay could be used more widely to quantify this non-antibody immune factor in other external secretions than milk and to investigate its biological importance. However, the lower detection limit will have to be improved by optimization of assay conditions to measure the lowest concentrations of LZ in urine (37, 38) .
